FDA Biologics (BLA & Biosimilars)Original article
Vaccines and Related Biological Products Advisory Committee June 18, 2026 Meeting Announcement - 06/18/2026
AdComMFLUSIVANeutral
AI Analysis
Summary
The FDA's Vaccines and Related Biological Products Advisory Committee is scheduled to meet on June 18, 2026 to discuss and make recommendations on the safety and effectiveness of MFLUSIVA, an influenza vaccine for persons 50 years and older, under BLA STN 125869/0.
Outcome Details
Vaccines and Related Biological Products Advisory Committee meeting scheduled to discuss and make recommendations on safety and effectiveness of MFLUSIVA
Importance:7/10
Sentiment:
0.00
vaccineinfluenzaadvisory committeeBLAFDA
Read the original article
Published by FDA Biologics (BLA & Biosimilars) on September 21, 2026 2:16 PM